JP2022506958A5 - - Google Patents
Info
- Publication number
- JP2022506958A5 JP2022506958A5 JP2021525119A JP2021525119A JP2022506958A5 JP 2022506958 A5 JP2022506958 A5 JP 2022506958A5 JP 2021525119 A JP2021525119 A JP 2021525119A JP 2021525119 A JP2021525119 A JP 2021525119A JP 2022506958 A5 JP2022506958 A5 JP 2022506958A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleoside
- composition according
- compound
- subscript
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760546P | 2018-11-13 | 2018-11-13 | |
| US62/760,546 | 2018-11-13 | ||
| PCT/US2019/060841 WO2020102142A1 (en) | 2018-11-13 | 2019-11-12 | Microrna compounds and methods for modulating mir-10b activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506958A JP2022506958A (ja) | 2022-01-17 |
| JP2022506958A5 true JP2022506958A5 (OSRAM) | 2022-10-03 |
Family
ID=68808539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525119A Pending JP2022506958A (ja) | 2018-11-13 | 2019-11-12 | Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220096517A1 (OSRAM) |
| EP (1) | EP3880310A1 (OSRAM) |
| JP (1) | JP2022506958A (OSRAM) |
| KR (1) | KR20210091732A (OSRAM) |
| CN (1) | CN112996568A (OSRAM) |
| AU (1) | AU2019381681A1 (OSRAM) |
| CA (1) | CA3117981A1 (OSRAM) |
| MA (1) | MA54226A (OSRAM) |
| TW (1) | TW202031268A (OSRAM) |
| WO (1) | WO2020102142A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236337B2 (en) | 2016-11-01 | 2022-02-01 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| WO2010022166A2 (en) * | 2008-08-19 | 2010-02-25 | Maine Institute For Human Genetics And Health | Micro rna (mirna) and neurofibromatosis type 1 : a role in diagnosis and therapy |
| NZ596608A (en) * | 2009-06-12 | 2014-01-31 | Santaris Pharma As | New potent anti apob antisense compounds |
| US9364495B2 (en) * | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
| WO2013034989A2 (en) * | 2011-09-07 | 2013-03-14 | 3-D Matrix, Ltd. | Microrna-based methods and assays for osteosarcoma |
| EP2841579B1 (en) * | 2012-04-25 | 2018-10-10 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| MY198759A (en) * | 2016-12-05 | 2023-09-23 | Regulus Therapeutics Inc | Modified oligonucleotides for treatment of polycystic kidney disease |
-
2019
- 2019-11-12 KR KR1020217016717A patent/KR20210091732A/ko not_active Withdrawn
- 2019-11-12 JP JP2021525119A patent/JP2022506958A/ja active Pending
- 2019-11-12 WO PCT/US2019/060841 patent/WO2020102142A1/en not_active Ceased
- 2019-11-12 CN CN201980074354.1A patent/CN112996568A/zh active Pending
- 2019-11-12 CA CA3117981A patent/CA3117981A1/en active Pending
- 2019-11-12 EP EP19817004.5A patent/EP3880310A1/en not_active Withdrawn
- 2019-11-12 US US17/290,298 patent/US20220096517A1/en not_active Abandoned
- 2019-11-12 TW TW108140918A patent/TW202031268A/zh unknown
- 2019-11-12 MA MA054226A patent/MA54226A/fr unknown
- 2019-11-12 AU AU2019381681A patent/AU2019381681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Messaoudi et al. | Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide | |
| JP7498230B2 (ja) | ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用 | |
| US9200285B2 (en) | Clusterin antisense therapy for treatment of cancer | |
| JP7558963B2 (ja) | 修飾されたマイクロｒｎａ及びがんの処置におけるその使用 | |
| US12371693B2 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| US11236337B2 (en) | 5-halouracil-modified microRNAs and their use in the treatment of cancer | |
| KR101843985B1 (ko) | 암을 치료하기 위한 조성물과 방법 | |
| JP2011515357A5 (OSRAM) | ||
| RU2535993C2 (ru) | Молекула rnai, нацеливающая тимидилатсинтазу и ее применение | |
| US12319913B2 (en) | 5-halouracil-modified microRNAs and their use in the treatment of cancer | |
| KR101843984B1 (ko) | 췌장암을 치료하기 위한 조성물과 방법 | |
| US20080274121A1 (en) | Inhibition of Angiogenesis by Mithramycin | |
| Leighl et al. | A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium | |
| JP2007525414A (ja) | スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分 | |
| JP7707184B2 (ja) | 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用 | |
| US20130296407A1 (en) | Combination Therapy for Cancer | |
| US20250327075A1 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| JP7498448B2 (ja) | ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| US20070270371A1 (en) | Dosing and scheduling of oligomers | |
| Xiong et al. | Therapeutic principles of gastrointestinal neoplasia: chemotherapy |